Sangamo Biosciences News (NASDAQ:SGMO)
| Latest Sangamo Biosciences News Headlines | | Date | Time | Source | | | 07/16/2008 | 4:05PM | PRNUS | Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
RICHMOND, Calif., July 16 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced that the company will release its second quarter 2008 financial results on Wednesday, July 23, 2008, after the market closes. The press release will be followed by a conference call at 2:00 p.m. PT, which will... More...>> |
| 07/09/2008 | 7:00AM | PRNUS | Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Gener
Transgenic Animals to be Developed for Therapeutic and Diagnostic Applications
ST. LOUIS and RICHMOND, Calif., July 9 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (NASDAQ:SIAL) and Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced a research and license agreement to provide Roche (SWX:ROG) with non-exclusive... More...>> |
| 06/30/2008 | 7:00AM | PRNUS | Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistan
Preclinical Animal Data Demonstrates Promising Therapeutic Strategy for HIV/AIDS
RICHMOND, Calif., June 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today the publication of data demonstrating that human immune system cells (CD4 T-cells) can be made resistant to HIV infection by treatment... More...>> |
| 06/18/2008 | 4:05PM | PRNUS | Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
Dow AgroSciences Will Sublicense Sangamo's Technology in Plant Agriculture Under the Trademark EXZACT(TM) Precision Traits
SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), announced today at the 2008 BIO International Convention that... More...>> |
| 06/08/2008 | 7:30PM | PRNUS | Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Presentation Details Statistically Significant and Clinically Relevant Results for SB-509 in Development for Treatment of Diabetic Neuropathy
SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today the presentation of encouraging Phase 1b clinical data from its ZFP Therapeutic(TM... More...>> |
| 06/06/2008 | 7:00AM | PRNUS | Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Sangamo Announces Completion of Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic Neuropathy
SAN FRANCISCO, June 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today the completion of patient enrollment into its Phase 2 clinical... More...>> |
| 06/05/2008 | 7:00AM | PRNUS | Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
ZFP Technology Accelerates Precision Gene Control, Trait Stacking in Commercial Crop Species
INDIANAPOLIS and RICHMOND, Calif., June 5 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today the successful completion of research milestones as part of their joint Research... More...>> |
| 05/29/2008 | 4:12PM | PRNUS | Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
RICHMOND, Calif., May 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on Sangamo's diabetic neuropathy programs at 1:40 p.m. (ET) on Friday, June 6, 2008, at the Canaccord Adams Diabetes and Obesity Conference... More...>> |
| 05/19/2008 | 7:00AM | PRNUS | Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISC
Progenitor Cell Mobilization Observed in Subjects with Critical Limb Ischemia Treated with ZFP Therapeutic
MIAMI, May 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today the presentation of data from a Phase 1 clinical trial of a zinc finger DNA-binding protein activator of vascular... More...>> |
| 05/14/2008 | 4:00PM | PRNUS | Sangamo BioSciences to Present at the Citi Investment Research Global Healthcare Conference
RICHMOND, Calif., May 14 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:30 a.m. (ET... More...>> |
| 05/13/2008 | 4:00PM | PRNUS | Sangamo BioSciences to Present at the 7th Annual JMP Securities Research Conference
RICHMOND, Calif., May 13 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 12:00 p.m. (ET... More...>> |
| 05/07/2008 | 4:00PM | PRNUS | Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
RICHMOND, Calif., May 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 7:40 p.m. (ET) on... More...>> |
| 04/30/2008 | 4:00PM | PRNUS | Sangamo BioSciences Reports First Quarter 2008 Financial Results
RICHMOND, Calif., April 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today reported first quarter 2008 financial results and accomplishments.
For the first quarter ended March 31, 2008, Sangamo reported a consolidated net loss of $8.0 million, or $0.20 per share, compared to a net loss of $5.4... More...>> |
| 04/28/2008 | 4:00PM | PRNUS | Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
RICHMOND, Calif., April 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO), a leader in the research and development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, announced today the nomination of Thomas G. Wiggans to the company's Board of Directors.
Mr... More...>> |
| 04/23/2008 | 4:00PM | PRNUS | Sangamo BioSciences Announces First Quarter Conference Call and Webcast
RICHMOND, Calif., April 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced that the company will release its first quarter 2008 financial results on Wednesday, April 30, 2008, after the market closes. The press release will be followed by a conference call at 2:00 p.m. PT, which will... More...>> |
| 04/15/2008 | 7:00AM | PRNUS | Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Resear
ZFN Modified Cells Show Glioblastoma Killing in the Presence of Dexamethasone in Mouse Tumor Model
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced the presentation of positive data in a mouse tumor model from its ZFP Therapeutic(TM) program for the treatment of glioblastoma... More...>> |
| 04/07/2008 | 7:00AM | PRNUS | Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
RICHMOND, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced that it had entered into a License Agreement with Open Monoclonal Technologies (OMT), a private company based in Palo Alto, California. Under this agreement, Sangamo will provide a non-exclusive, worldwide... More...>> |
| 03/24/2008 | 7:00AM | PRNUS | Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of
ZFN Technology has Broad Applications in Research, Drug Development and Therapeutics
ST. LOUIS and RICHMOND, Calif., March 24 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (NASDAQ:SIAL) and Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today the publication of data demonstrating the use of Sangamo's zinc finger... More...>> |
| 03/11/2008 | 4:00PM | PRNUS | Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
RICHMOND, Calif., March 11 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 9:30 a.m. (ET... More...>> |
| 02/27/2008 | 7:00AM | PRNUS | Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmace
Companies Agree to Expanded Access to ZFN Technology To Potentially Improve Protein Production
RICHMOND, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced that it has entered into a second Research and License Agreement with Genentech, Inc. expanding on the original agreement... More...>> |
|
|
|